IP Library Granted Patent US 8,188,216
Granted Patent B2
US 8,188,216 · App. 10/961,856 · Granted May 29, 2012

Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,188,216
App. No.
10/961,856
Granted
May 29, 2012
Kind
B2
Abstract

A library of macrocyclic compounds of the formula (I) where part (A) is a bivalent radical, a —(CH 2 ) y — bivalent radical or a covalent bond; where part (B) is a bivalent radical, a —(CH 2 ) z — bivalent radical, or a covalent bond; where part (C) is a bivalent radical, a —(CH2) t - bivalent radical, or a covalent bond; and where part (T) is a -Y-L-Z- radical wherein Y is CH 2 or CO, Z is NH or O and L is a bivalent radical. These compounds are useful for carrying out screening assays or as intermediates for the synthesis of other compounds of pharmaceutical interest. A process for their preparation of these compounds in a combinatorial manner, is also disclosed.

Claims (85)

1. A process for preparing a library of compounds of the formula (1),

where part (A) is a

bivalent radical having its —NH— group linked to the terminal carbonyl group of part (D) shown below

proline or hydroxyproline;

where part (B) is a

bivalent radical having its —NH— group linked to part (A), proline or hydroxyproline, a —(CH 2 ) z — bivalent radical, or a covalent bond;

where part (C) is a

bivalent radical having its —NH— group linked to part (B), proline or hydroxyproline, a —(CH 2 ) t — bivalent radical, or a covalent bond;

where part (T) is selected from the group consisting of

wherein (Q) indicates the site of a covalent bond to part (C) of formula 1 and (N) indicates the site of a covalent bond to N—X of formula 1;

M is selected from the group consisting of —O—, —S— and —NH—;

R 10 and R 11 are independently —H; and

n1, n2, n3, n4, n5, n6 and n7 are independently 1 or 2; and

where X is a monovalent group selected from the group consisting of: —SO 2 —Ar, —SO 2 —CH 3 , —SO 2 —CF 3 , —H, —COH, —CO—CH 3 , —CO—Ar, —CO—R a , —CO—NHR a , —CO—NHAr, —CO—O-tBu, —CO—O—CH 2 —Ar,

the latter hereinafter referred to as part (E);

Ar is an aromatic group, substituted aromatic group or a heteroaromatic group;

a is an integer selected from the group consisting of 0, 1 and 2;

R a is a monovalent group —(CH 2 ) n —CH 3 or —(CH 2 ) n —Ar with n being an integer from 1 to 16;

R 0 , R 1 , R 2 , R 3 and R 4 being independently selected from the group consisting of:

wherein (V) indicates the site of bonding to the attached carbon atom of part (A), part (B), part (C), part (D) or part (E);

R 5 , R 6 1 and R 6 2 each being a monovalent radical independently selected from the group consisting of: —H, —SO 2 —CH 3 , —SO 2 —CF 3 , —COH, —COCH 3 , —CO—Ar, —CO—R a or —CO—NHR a wherein R a is defined as above, —CONHAr, —COO-tBu and —COO—CH 2 —Ar, said radical being or not substituted by at least one monovalent group selected from the group consisting of: —O—CH 3 , —CH 3 , —NO 2 , —NH 2 , —NH—CH 3 , —N(CH 3 ) 2 , —CO—OH, —CO—O—CH 3 , —CO—CH 3 , —CO—NH 2 , OH, F, Cl, Br and I;

R 7 is a monovalent radical selected from the group consisting of:

—H, —COH, —CO—CH 3 , NHOH, NHOR, NHR, —CO—R a wherein R a is defined as above, —CO—Ar and —CO-tBu, said radical being substituted or not by at least one substituent selected from the group consisting of: —O—CH 3 , —CH 3 , —NO 2 , —NH 2 , —NH—CH 3 , —N(CH 3 ) 2 , —CO—OH, —CO—O—CH 3 , —CO—CH 3 , —CO—NH 2 , —OH, —F, —Cl, —Br and —I;

R 8 is a monovalent radical selected from the group consisting of:

—OH, —NH 2 , —OCH 3 , —NHCH 3 , —O-tBu and —O—CH 2 —Ar, said radical being substituted or not by at least one group selected from the group consisting of:

—O—CH 3 , —CH 3 , —NO 2 , —NH—CH 3 , —N(CH 3 ) 2 , —CO—OH, —CO—O—CH 3 , —CO—CH 3 , —CO—NH 2 , —OH, —F, —Cl, —Br and —I;

R 9 is a monovalent radical selected from the group consisting of:

—H, -tBu, —CO—CH 3 , —COAr, —CO—R a wherein R a is defined as above and —COH, said radicals substituted or not by at least one monovalent group selected from the group consisting of:

—O—CH 3 , —CH 3 , —NO 2 , —NH—CH 3 , —N(CH 3 ) 2 , —CO—OH, —CO—O—CH 3 , —CO—CH 3 , —CO—NH 2 , OH, F, Cl, Br and I;

wherein x, y, z and t are integers each independently selected from the group consisting of 0, 1 and 2;

the process comprising the steps of:

a) preparing by coupling a first building block derived from natural or synthetic amino-acids, said first building block being of the formula:

wherein X and R 1 are as defined above, and A, B and C are as defined for part (A), part (B) and part (C) above, respectively;

Sp is

wherein (P) indicates the site of a covalent bond to P, (Q) indicates the site of a covalent bond to C, and P is polystyrene, PEG-polystyrene, polyacrylamide or other solid phase synthesis resin;

b) coupling the first building block prepared in step a) with a second building block hereafter called “tether”, of the formula:

HO-T-PG Z

wherein T refers to part (T) as defined above and PG Z is a protecting group, with the exception that (N) shown above in the definition of part (T) is replaced by (HO) indicating the site of a covalent bond to HO and (Q) shown above in the definition of part (T) is replaced by (PG Z ) indicating the site of a covalent bond to PG Z ; and

c) removing the protection group PG Z from the compound obtained in step b); and

d) carrying out a macrocyclization of the unprotected product obtained in step c) and a cleavage in order to obtain the compound of the formula 1.

2. A process according to claim 1 , wherein part (A), part (B) or part (C) is Arg, the process further comprising the steps of:

a) utilizing a protected ornithine (Orn) residue as a surrogate for Arg,

b) carrying out a selective deprotection of the protecting group on the Orn side chain, and

c) reacting with a protected guanylating reagent to provide the protected Arg element.

3. A process for preparing a library of compounds of formula (8):

comprising the steps of:

a) coupling an amino-acid of the formula (A):

wherein PG α is an amine protecting group, R 3 is defined as in claim 1 and PG 3 is a protecting group, with a compound of the formula:

H-Sp-P

wherein,

Sp is

wherein (P) indicates the site of a covalent bond to P, (H) indicates the site of a covalent bond to H, and P is polystyrene, in order to obtain a compound of the formula (1)

b) removing the amine protection group PGα from the compound of the formula (1) to obtain the corresponding compound of the formula (2):

c) coupling the compound of the formula (2) with another amino-acid of the formula (B):

wherein PGα is defined as above, R 2 is defined as in claim 1 and PG 2 is a protecting group, in order to obtain a compound of the formula (3):

d) removing the amine protection group PGα from the compound of the formula (3) to obtain the corresponding compound of the formula (4):

e) either coupling the compound of the formula (4) with a further amino-acid of the formula (C):

wherein R 1 is defined as in claim 1 , R is CH 3 , Ar, CF 3 or

and PG 1 is a protecting group, in order to obtain a compound of the formula (5):

and coupling said compound of the formula (5) under Mitsunobu conditions with an alcohol of the formula (D):

HO—CH 2 -L-ZPGz  (D)

wherein L is selected from the group consisting of:

and

Z is NH and (Z) indicates the site of a covalent bond to Z of formula (D) and (CH 2 ) indicates the site of a covalent bond to CH 2 of formula (D);

M a is selected from the group consisting of —O—, —S— and —NH—;

R 10a and R 11a are independently —H;

m1, m3, m4, m5, m6 and m7 are independently 1 or 2;

m2 is 0 or 1; and

PG Z is a protecting group, in order to obtain the compound of the formula (6):

or coupling the compound of the formula (4) with a compound of the formula (E):

wherein R, L, R 1 , PG 1 , PG 2 , Z and PG z are defined as above, in order to obtain directly the compound of the formula (6);

f) removing the protecting group PG z from the compound of the formula (6) to obtain the corresponding compound of the formula (7):

and

g) carrying out a macrocyclization of the compound of the formula (7) and a cleavage in order to obtain the compound of the formula (8).

4. A process for preparing a library of compounds of the formula (9), which comprises the process of claim 3 and further comprises removing the protecting group PG 1 , PG 2 and PG 3 of the compound of formula (8) to yield the requested compound of the formula (9):

5. A process for preparing a library of compounds of formula (10):

which comprises the process of claim 3 and further comprises removing the sulfonamide portion of the compound of formula (8) to yield the compound of formula (10).

6. A process for preparing a library of compounds of formula (11):

which comprises the process of claim 5 and further comprises coupling the free amine of the compound of formula (10) with an acid of formula HX, wherein X is as defined in claim 1 , to yield the compound of formula (11).

7. A process for preparing a library of compounds of formula (12):

which comprises the process of claim 6 and further comprises removing the orthogonal protecting groups PG 1 , PG 2 and PG 3 of the compound of formula (11), to yield the compound of formula (12).

8. A process according to any one of claim 1 , 3 , 6 or 7 , wherein each of PG 1 , PG 2 , PG 3 , PG 4 and PG Z have independently the same meanings as the radical R 5 , R 6 1 , R 6 2 , R 7 , R 8 or R 9 as defined in claim 1 .

9. A process according to claim 8 , wherein at least one of PG 1 , PG 2 , PG 3 , PG 4 and PG z is a carbamate or a trityl group.

10. A process according to claim 9 , wherein the carbamate is selected from the group consisting of Boc, Fmoc and Ddz.

11. A process according to claim 9 , wherein the trityl is selected from the group consisting of Trt and Mmt.

Assignments (4)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 044949, FRAME 0634 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065610/0460 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Dec 22, 2017
From: OCERA THERAPEUTICS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 044949/0634 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2014
From: TRANZYME PHARMA INC.
To: OCERA THERAPEUTICS, INC.
Reel/Frame 031994/0084 →
CHANGE OF NAME Recorded Dec 14, 2004
From: NEOKIMIA INC.
To: TRANZYME PHARMA INC.
Reel/Frame 015458/0105 →